NEW YORK, July 14, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Neurotrope, Inc. (NASDAQ:NTRP) who purchased shares between January 7, 2016, and April 28, 2017. The action, which was filed in the U.S. District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the Class Period Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
Shareholders have until July 17, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/neurotrope-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Apple Turns 50: From Garage Startup to AI Crossroads
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



